What are the clinical benefits of recombinant gonadotrophins? The good,the bad and the ugly

Review OA: bronze CC0
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-03 ⓘ

This paper analyzes the current market landscape for ovulation induction drugs by framing the competitive dynamics between key players as a narrative of alliances against a dominant force.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

After recently spending 2 days listening to a group of very distinguished professors and scientists with many years of experience in ovulation induction, and having read the recent debate on Puregon Just as in the original movie, the good guy and the ugly guy join forces to fight the bad guy in their quest for the hidden gold (the market, in our movie).

My notes (saved in your browser only)

MeSH descriptors

Clomiphene Fertilization in Vitro Follicle Stimulating Hormone Ovulation Induction Clomiphene Female Follicle Stimulating Hormone Humans Recombinant Proteins Recombinant Proteins

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (8)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T20:58:57.924351+00:00
License: CC0 · commercial use OK